Screening for Active Compounds Targeting Human Natural Killer Cell Activation Identifying Daphnetin as an Enhancer for IFN-γ Production and Direct Cytotoxicity.
Screening for Active Compounds Targeting Human Natural Killer Cell Activation Identifying Daphnetin as an Enhancer for IFN-γ Production and Direct Cytotoxicity.
复制标题
筛选针对人类自然杀伤细胞激活的活性化合物 鉴定瑞香素作为 IFN-γ 产生和直接细胞毒性的增强剂
DOI:
10.3389/fimmu.2021.680611
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Deng Y
中科院分区:
文献类型:
--
作者:
Yao B;Yang Q;Yang Y;Li Y;Peng H;Wu S;Wang L;Zhang S;Huang M;Wang E;Xiong P;Luo T;Li L;Jia S;Deng Y;Deng Y
Natural killer (NK) cells are a potent weapon against tumor and viral infection. Finding active compounds with the capacity of enhancing NK cell effector functions will be effective to develop new anti-cancer drugs. In this study, we initially screened 287 commercially available active compounds by co-culturing with peripheral blood mononuclear cells (PBMCs). We found that five compounds, namely, Daphnetin, MK-8617, LW6, JIB-04, and IOX1, increased the IFN-γ+ NK cell ratio in the presence of IL-12. Further studies using purified human primary NK cells revealed that Daphnetin directly promoted NK cell IFN-γ production in the presence of IL-12 but not IL-15, while the other four compounds acted on NK cells indirectly. Daphnetin also improved the direct cytotoxicity of NK cells against tumor cells in the presence of IL-12. Through RNA-sequencing, we found that PI3K-Akt-mTOR signaling acted as a central pathway in Daphnetin-mediated NK cell activation in the presence of IL-12. This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-γ production and cytotoxicity in NK cells promoted by Daphnetin. Collectively, we identify a natural product, Daphnetin, with the capacity of promoting human NK cell activation via PI3K-Akt-mTOR signaling in the presence of IL-12. Our current study opens up a new potential application for Daphnetin as a complementary immunomodulator for cancer treatments.
登录
查看更多内容
影响因子:
7.3
作者:
Ali AK;Nandagopal N;Lee SH
通讯作者:
Lee SH
影响因子:
4.8
作者:
Ji, Jianjian;Ge, Xiaoyin;Shi, Liyun
通讯作者:
Shi, Liyun
影响因子:
4.8
作者:
Chen, Zhimin;Sun, Xiaoxiao;Yu, Qiang
通讯作者:
Yu, Qiang
影响因子:
7.9
作者:
Fan, Xiaoye;Xie, Min;Zhang, Songling
通讯作者:
Zhang, Songling
影响因子:
7.2
作者:
Alspach, Elise;Lussier, Danielle M.;Schreiber, Robert D.
通讯作者:
Schreiber, Robert D.